134 related articles for article (PubMed ID: 22402257)
1. Suppression of ovarian activity with a low-dose 21/7-day regimen oral contraceptive containing ethinylestradiol 20 mcg/drospirenone 3 mg in Japanese and Caucasian women.
Anzai Y; Heger-Mahn D; Schellschmidt I; Marr J
Contraception; 2012 Jul; 86(1):28-34. PubMed ID: 22402257
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: Results of a phase II dose-finding pilot study.
Duijkers IJ; Klipping C; Zimmerman Y; Appels N; Jost M; Maillard C; Mawet M; Foidart JM; Coelingh Bennink HJ
Eur J Contracept Reprod Health Care; 2015; 20(6):476-89. PubMed ID: 26394847
[TBL] [Abstract][Full Text] [Related]
3. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study.
Dinger J; Assmann A; Möhner S; Minh TD
J Fam Plann Reprod Health Care; 2010 Jul; 36(3):123-9. PubMed ID: 20659364
[TBL] [Abstract][Full Text] [Related]
4. Effects of an oral contraceptive containing estetrol and drospirenone on ovarian function.
Duijkers I; Klipping C; Kinet V; Jost M; Bastidas A; Foidart JM
Contraception; 2021 Jun; 103(6):386-393. PubMed ID: 33689786
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in a 24+4-day regimen in China].
Caiyan W; Wen D; Qinping L; Huan S; Ziyan H; Liangdan T; Zheng'ai X; Yufeng L; Shulan Z; Baihua D; Xiaoyan X; Mulan R; Xiaomao L; Youdi X; Zhisong M; Meiqing X; Hongyu W; Zirong H
Zhonghua Fu Chan Ke Za Zhi; 2014 May; 49(5):355-9. PubMed ID: 25030732
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters.
Douxfils J; Klipping C; Duijkers I; Kinet V; Mawet M; Maillard C; Jost M; Rosing J; Foidart JM
Contraception; 2020 Dec; 102(6):396-402. PubMed ID: 32956694
[TBL] [Abstract][Full Text] [Related]
7. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
[TBL] [Abstract][Full Text] [Related]
8. Effects of an extended flexible regimen of an oral contraceptive pill containing 20 μg ethinylestradiol and 3 mg drospirenone on menstrual-related symptoms: a randomised controlled trial.
Machado RB; Pompei LM; Badalotti M; Ferriani R; Cruz AM; Nahas E; Maia H
Eur J Contracept Reprod Health Care; 2017 Feb; 22(1):11-16. PubMed ID: 27684740
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial.
Koltun W; Lucky AW; Thiboutot D; Niknian M; Sampson-Landers C; Korner P; Marr J
Contraception; 2008 Apr; 77(4):249-56. PubMed ID: 18342647
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen.
Mansour D; Verhoeven C; Sommer W; Weisberg E; Taneepanichskul S; Melis GB; Sundström-Poromaa I; Korver T
Eur J Contracept Reprod Health Care; 2011 Dec; 16(6):430-43. PubMed ID: 21995590
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen.
Hernádi L; Marr J; Trummer D; De Leo V; Petraglia F
Contraception; 2009 Jul; 80(1):18-24. PubMed ID: 19501211
[TBL] [Abstract][Full Text] [Related]
12. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen.
Klipping C; Duijkers I; Trummer D; Marr J
Contraception; 2008 Jul; 78(1):16-25. PubMed ID: 18555813
[TBL] [Abstract][Full Text] [Related]
13. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen.
Marr J; Gerlinger C; Kunz M
Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):91-5. PubMed ID: 22391750
[TBL] [Abstract][Full Text] [Related]
14. Ovulatory effects of three oral contraceptive regimens: a randomized, open-label, descriptive trial.
Seidman L; Kroll R; Howard B; Ricciotti N; Hsieh J; Weiss H
Contraception; 2015 Jun; 91(6):495-502. PubMed ID: 25746294
[TBL] [Abstract][Full Text] [Related]
15. Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris.
Fenton C; Wellington K; Moen MD; Robinson DM
Drugs; 2007; 67(12):1749-65. PubMed ID: 17683173
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of ethinylestradiol/drospirenone for premenstrual symptoms in Japanese patients with dysmenorrhea: Open-label pilot study.
Takeda T; Kondo A; Koga S; Hayakawa J; Hayakawa K; Hiramatsu K; Yaegashi N
J Obstet Gynaecol Res; 2015 Oct; 41(10):1584-90. PubMed ID: 26310836
[TBL] [Abstract][Full Text] [Related]
17. Effects of low dose oral contraceptive pill containing drospirenone/ethinylestradiol in patients with endometrioma.
Taniguchi F; Enatsu A; Ota I; Toda T; Arata K; Harada T
Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():116-20. PubMed ID: 26115056
[TBL] [Abstract][Full Text] [Related]
18. Cycle control and bleeding pattern of a 24/4 regimen of drospirenone 3 mg/ethinylestradiol 20 μg compared with a 21/7 regimen of desogestrel 150 μg/ethinylestradiol 20 μg: a pooled analysis.
Anttila L; Neunteufel W; Petraglia F; Marr J; Kunz M
Clin Drug Investig; 2011; 31(8):519-525. PubMed ID: 21721590
[TBL] [Abstract][Full Text] [Related]
19. A study of cycle control, side effects and client's satisfaction of a low dose combined contraceptive containing ethinylestradiol/drospirenone (24/4 regimen).
Chaiyasit N; Taneepanichskul S
J Med Assoc Thai; 2010 May; 93(5):517-22. PubMed ID: 20524436
[TBL] [Abstract][Full Text] [Related]
20. Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study.
Kelly S; Davies E; Fearns S; McKinnon C; Carter R; Gerlinger C; Smithers A
Clin Drug Investig; 2010; 30(5):325-36. PubMed ID: 20384388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
